Bispecific antibody News and Research

RSS

Integral Molecular and Merus collaborate to develop bispecific antibody therapeutics

Integral Molecular, the industry leader in the discovery of monoclonal antibodies against membrane proteins, and Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced that they have entered into a collaboration on multiple undisclosed targets.

12 Dec 2018

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

Innovation in immuno-oncology is exploding and new technologies that are set to benefit many patients with cancer are being showcased in the highly diverse array of topics to be discussed at the ESMO Immuno-Oncology Congress, to be held 13-16 December in Geneva, Switzerland.

11 Dec 2018

Scientists equip new virus that kills carcinoma cells with protein

Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system.

19 Nov 2018

VTT, Dyadic to present data highlighting achievements in development of fungal production platform

VTT and Dyadic International, Inc., today announced that VTT scientists will present the excellent results in their collaboration over the past two years at two international conferences: AAPS PharmSci on November 7th in Washington DC and PEGS Europe on November 14th in Lisbon.

5 Nov 2018

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

Amgen today announced that new clinical data will be presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, Dec. 1-4, 2018. Data across an array of malignancies will be featured in 45 abstracts, including nine oral presentations, from the Company’s broad portfolio andearly-stage pipeline.

From AMGEN 5 Nov 2018

New nuclear medicine approach shows potential for precision treatment of solid tumors

A novel nuclear medicine approach is showing great promise for precision treatment of solid tumors in many types of cancer--including lung, breast, pancreas and ovarian in adults and glioma, neuroblastoma and sarcoma in children.

26 Jun 2018

MD Anderson and Amgen collaborate to accelerate early-stage oncology therapies

The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.

1 Jun 2018

Scientists engineer bi-specific antibodies that attract immune killers directly to cancer cells

Our immune system's arsenal of defenses usually protects us from cancer. But sometimes, cancer cells overwhelm or evade this elaborate defense system.

30 May 2018

Novel oncolytic virus expressing BiTE molecule elicits T cell-mediated killing of tumor cells

In a research article published in EMBO Molecular Medicine, a group of scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.

13 Mar 2018

Researchers reveal potential of multivalent antibodies for HIV prevention, treatment and cure

The ability of HIV to mutate has been a major challenge to vaccine development. As the body produces antibodies to target the outer HIV envelope protein, this protein changes, thwarting the circulating antibodies' ability to neutralize it.

18 Jan 2018

Researchers develop new, three-step system to eliminate colorectal cancer

Researchers at Memorial Sloan Kettering Cancer Center in New York City and Massachusetts Institute of Technology in Boston have developed a new, three-step system that uses nuclear medicine to target and eliminate colorectal cancer.

2 Nov 2017

Researchers develop new approach to efficiently produce versatile antibody therapies

A group of researchers has developed an approach to efficiently produce antibodies that can bind to two different target molecules simultaneously, a long-desired innovation in the field of cancer immunotherapy.

29 Aug 2017

IDIBELL scientists develop oncolytic virus capable of redirecting immune system to attack cancer cells

Researchers of the Cancer Virotherapy Research Group of Bellvitge Biomedicine Research Institute, led by Dr. Ramon Alemany, have developed an oncolytic virus capable of redirecting the patient's immune system against their tumor cells.

16 Feb 2017

Novel Trojan Horse antibody strategy may target Ebola's Achilles' heel

In research published online today in Science, a team of scientists describe a new therapeutic strategy to target a hidden Achilles' heel shared by all known types of Ebola virus.

8 Sep 2016

Immunotherapy innovations in oncology: an interview with Robert LaCaze

The body’s immune system is an excellent weapon against many diseases. For more than 100 years, immunology and immunotherapy have played an ever-increasing role in the understanding and treatment of cancer.

8 Aug 2016

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers at Albert Einstein College of Medicine and the U.S. Army Medical Research Institute of Infectious Diseases have engineered the first antibodies that can potently neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever.

13 Jan 2016

F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

F-star today announced that it has entered into a collaboration and license agreement with AbbVie to research and develop bispecific antibodies in immuno-oncology. Financial terms were not disclosed.

11 Jan 2016

Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune Pharmaceuticals Inc. a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced it has entered into an exclusive license with Atlante Biotech SAS, to the patents and know-how for a new format of bispecific antibodies.

29 Dec 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015